Sabby Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Sabby Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,868	Closed	-$57.9K	–	87
2023 Q3	$57.9K	Sell	2,868 -2,287	-44%	-$44.4K	0.04%	60
2023 Q2	$134K	Sell	5,155 -12,515	-71%	-$358K	0.11%	56
2023 Q1	$368K	Sell	17,670 -7,330	-29%	-$164K	0.32%	29
2022 Q4	$510K	Sell	25,000 -278	-1%	-$5.24K	0.45%	27
2022 Q3	$698K	Buy	25,278 +250	+1%	+$7.19K	0.88%	28
2022 Q2	$661K	Buy	25,028 +8,666	+53%	+$385K	0.45%	41
2022 Q1	$1.31M	Buy	16,362 +3,418	+26%	+$422K	0.2%	34
2021 Q4	$2.64M	Buy	12,944 +2,944	+29%	+$735K	0.38%	42
2021 Q3	$3.23M	Sell	10,000 -3,553	-26%	-$1.04M	0.44%	32
2021 Q2	$3.52M	Buy	13,553 +9,406	+227%	+$2.87M	0.5%	23
2021 Q1	$1.6M	Buy	+4,147	New	+$1.67M	0.31%	62

Other funds holding VINC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Sabby Management's VINC Position: Q4 2023 in Review

Sabby Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2023, closing a stake of 2,868 shares — an estimated $57.9K sold.

Sabby Management first reported a position in VINC in Q1 2021 and held it in 11 quarters. The position peaked at $3.52M in Q2 2021. 32 funds tracked by Wall St. Rank hold VINC as of Q4 2023.

Sabby Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Sabby Management sold 2,868 Vincerx Pharma, Inc. Common Stock shares in Q4 2023, an estimated $57.9K.
Sabby Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Sabby Management's Vincerx Pharma, Inc. Common Stock position peaked at $3.52M in Q2 2021.
32 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.